What the studies show
In the only sustained-dosing study, IGF-1, body fat, lean mass and bone density did not change significantly over 16 weeks.
“In the present study, the biological impact of this hexarelin schedule on the GH-IGF-I axis seems to be minimal.”
Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.
- 1Rahim A, et al. Growth hormone status during long-term hexarelin therapy.J Clin Endocrinol Metab, 1998;83:1644–164916 weeks; GH response attenuates, IGF-1 and body composition unchanged.
In context
Hexarelin is a synthetic six-amino-acid growth-hormone-releasing peptide. Single doses cause a strong, well-documented growth-hormone spike in humans, but the one study of continued use showed the response fades within weeks and that IGF-1 and body composition did not meaningfully change. It was never developed into an approved medicine, and the muscle, fat-loss and cardiac claims made for it have no controlled human evidence.
Hexarelin is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Hexarelin proven to help with body composition?
What studies are behind the grade?
Is Hexarelin approved for this?
Other outcomes for Hexarelin
- CGrowth hormone releaseMultiple acute studies + 1 chronic study
- DCardiac effectsMechanistic only
- CSafety in humansadverseEarly-phase
Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →